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Abstract
Kaposi’s sarcoma (KS) is an AIDS-defining cancer caused by the KS-associated herpesvirus
(KSHV). Unanswered questions regarding KS are its cellular ontology and the conditions con-
ducive to viral oncogenesis. We identify PDGFRA(+)/SCA-1(+) bone marrow-derived mesen-
chymal stem cells (Pα(+)S MSCs) as KS spindle-cell progenitors and found that pro-angiogenic
environmental conditions typical of KS are critical for KSHV sarcomagenesis. This is because
growth in KS-like conditions generates a de-repressed KSHV epigenome allowing oncogenic
KSHV gene expression in infected Pα(+)S MSCs. Furthermore, these growth conditions allow
KSHV-infected Pα(+)S MSCs to overcome KSHV-driven oncogene-induced senescence and
cell cycle arrest via a PDGFRA-signaling mechanism; thus identifying PDGFRA not only as a
phenotypic determinant for KS-progenitors but also as a critical enabler for viral oncogenesis.
Author summary
Identification of the KS progenitor cell creates the possibility of studying viral oncogenesis
and its determinants from its initial steps as a continuum. It also increases our under-
standing of pathogenic mechanisms and disease preferential tropism. Hereby we identify
Pα(+)S-MSCs as KS progenitors, in which KSHV infection has oncogenic consequences;
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only when these cells are in a pro-angiogenic environment in which PDGFRA activation
enables an oncogenic de-repressed KSHV epigenome. These results identify a KS-progen-
itor population in the Pα(+)S-MSCs and point to pro-angiogenic environmental condi-
tions as essential for oncogenic viral gene expression and transformation. We designed a
novel model of KSHV oncogenesis, creating a very robust platform to identify KSHV
oncogenic pathways and their relationship with cellular lineages and extracellular growth
environments.
Introduction
Viral cancers account for up to 12% of all human cancers and are characterized by the long
incubation periods and the fact that the majority of infected individuals do not develop cancer.
This is consequence of the need for specific host environmental factors or conditions such as
immunosuppression, which are necessary to enable the expression of the oncogenic viral gene
expression programs leading to full viral-mediated cellular transformation [1]. Kaposi’s sar-
coma (KS) is an AIDS-defining cancer and a major global health challenge caused by the
Kaposi’s sarcoma-associated herpesvirus (KSHV) [2–4]. It is characterized by the proliferation
of spindle-shaped cells (SC), inflammatory infiltrate and abundant angiogenesis with blood
vessel erythrocyte extravasation [2–5]. KS presents in 4 different clinical forms: classical,
endemic, iatrogenic and epidemic/AIDS-associated. Classical KS affects mostly elderly indi-
viduals of Ashkenazy Jews or Mediterranean descent and more recently at-risk populations
such as men who have sex with men (MSM). Endemic KS affects children, men, and women
in Sub-Saharan Africa. Iatrogenic KS is characteristic of transplant immunosuppression, in
particular, renal transplant, and epidemic or AIDS-associated KS predominantly affects MSMs
infected with HIV [4]. AIDS-associated immunosuppression and HIV constitute important
KS co-factors, yet other host factors may account for the oncogenicity of KSHV and HIV co-
infection in specific “at-risk” populations [6]. Although the incidence of AIDS-KS in the west-
ern world has declined since the implementation of ART, more than 50% of advanced
AIDS-KS patients never achieve total remission [6–8]. Moreover, KSHV prevalence and KS
appear to be increasing in ART-treated HIV-infected patients with controlled viremias [9, 10].
Critical pending questions on KS are its cellular ontology and the conditions conducive to
viral pathogenicity, which are important to understanding KSHV oncogeneic mechanisms
that could lead to prevention approaches or the discovery of therapeutic targets.
The origins of KS spindle cells (SC) have long been debated, as these cells express markers
of both lymphatic and blood vessel endothelium (podoplanin, VEGFR3, VEGF C and D,
CXCR4, DLL4, VEGFR1, CXCL12, CD34) [11, 12], as well of dendritic cells (Factor XIII),
macrophages (CD68), smooth muscle cells (SMA)[2] and mesenchymal stem cells (vimentin,
PDGFRA) [13, 14]. This remarkable heterogeneity, together with the multifocal manifestation
of many KS cases, suggests the existence of a circulating progenitor such as mesenchymal stem
cells or endothelial cell progenitors [6, 15–17]. Spindle cell precursors were found to be
increased in the blood of AIDS-KS patients, which upon KSHV infection and or inflammatory
conditions may further differentiate into endothelial, smooth muscle, fibroblastic and myofi-
broblastic cells [18–20].
KSHV encodes a plethora of latent and lytic genes with pathogenic and oncogenic potential
[2, 3]. KS lesions are composed of SC latently infected with KSHV, as well as cells expressing
lytic genes that have been implicated in the development of the KS angioproliferative pheno-
type via paracrine and autocrine mechanisms [2, 3, 5, 21–23]. These mechanisms are mediated
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in part by the ability of lytic viral genes such as the G protein-coupled receptor (vGPCR/
ORF74), K1 and K15, to upregulate angiogenesis and KS-cell growth factors [2, 3, 14, 21].
Although KSHV infection results in important morphological and transcriptional changes
that convey traits of malignant transformation, few KSHV-infected cellular types had become
fully tumorigenic [2, 5]. They are the basis for models of KSHV-tumorigenesis in murine, rat
and human cells [24–28]. In a KSHV tumorigenesis model in nude mice generated by trans-
fecting KSHVBac36 to mouse endothelial lineage cells [26], we found that malignancy was
only manifested in vivo and occurred with concomitant upregulation of oncogenic KSHV lytic
genes, angiogenesis growth factors and their tyrosine kinase receptors that are characteristic of
human KS lesions [2, 26]. Using this model we show that the most prominently activated tyro-
sine kinase was PDGFRA [14], which was activated by lytic KSHV genes via a ligand-mediated
mechanism and necessary for KSHV sarcomagenesis [14]. More importantly, PDGFRA was
prominently expressed and phosphorylated in the vast majority of AIDS-KS tumors [14]. This
together with the relative success of Imatinib Phase II trials targeting this receptor in KS [29]
and the fact that PDGFRA is a driver of many sarcomas identified PDGFRA as an oncogenic
driver in KS [14].
Viral cancers like KS are the consequence of infection with oncoviruses that evolved power-
ful mechanisms to persist and replicate through deregulation of host oncogenic pathways—
such as PDGFRA signaling—conveying cancer hallmarks to the infected cell [1]. In searching
for the identity of the oncogenic KS progenitor, we reasoned that if KSHV evolved its molecu-
lar machinery to activate PDGFRA signaling, a plausible oncogenic progenitor should be a
pluripotent cell where PDGFRA plays a major proliferative and survival role, such as mesen-
chymal stem cell (MSC) [30]. This would also be consistent with the mesenchymal origin of
sarcomas, many of which are driven by PDGFRA [31–33]. PDGFRA is a specific mesenchymal
lineage phenotypic marker, and together with the stem cell antigen-1 (Sca-1), is used to iden-
tify pluripotent mesenchymal stem cells (Pα(+)S- MSCs) [30]. Pα(+)S-MSCs have primitive
characteristics consistent with conventional MSC populations and an in vitro differentiation
assay showed that single Pα(+)S-derived MSCs differentiated not only into chondrocytes and
osteocytes but also into endothelial cells [30]. We hypothesized that PDGFRA-positive/SCA1-
positive MSCs would likely serve as a natural target of KSHV infection, thus prompting onco-
genic transformation via a PDGFRA-driven mechanism. The possibility of a mesenchymal
progenitor for KS has been suggested by the work of several groups [28, 34–38]. In particular,
mesenchymal and precursor markers are parts of the immunohistochemical features of KS
[34]. In addition, rat and human MSCs from bone marrow and other origins are susceptible to
KSHV infection [28, 35, 37, 38] and KSHV infection promoted multi-lineage differentiation
and mesenchymal-to-endothelial transition into human oral MSC, providing evidence for
human oral MSCs being a potential origin of Kaposi sarcoma cells [36].
Hereby we study the infection of murine and human PDGFRA positive MSC progenitors to
generate a “de novo”, cell type-defined tumorigenesis system that could have the advantage to
follow the process of tumorigenesis from a primary non-transformed cell, as well as identifying
oncogenesis environmental conditions and molecular mechanisms critical for this process. In
the present manuscript, we identify PDGFRA(+)/SCA-1(+) bone marrow-derived mesenchy-
mal stem cells (Pα(+)S MSCs) as KS spindle cell progenitors and we also identify pro-angio-
genic environmental conditions typical of KS as critical for KSHV sarcomagenesis. We found
that growth in KS-like conditions generates a de-repressed KSHV epigenome, allowing onco-
genic KSHV gene expression in infected Pα(+)S MSCs. Furthermore, these growth conditions
allow KSHV-infected Pα(+)S MSCs to overcome KSHV-driven oncogene-induced senescence
and cell cycle arrest via a PDGFRA-signaling mechanism; thus identifying PDGFRA not only as
a phenotypic determinant for KS-progenitors but also as a critical enabler for viral oncogenesis.
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Results
KSHV latency establishment in mouse bone marrow-derived MSC
In order to identify spindle-cell KS progenitors, we purified adherent spindle-shaped mouse
bone marrow-derived MSCs, from different mouse donors, that were positive for PDGFRA
(60%) and the stem cell antigen SCA-1 (100%) (Fig 1A), as previously described [30, 39]. We
sorted for PDGFRA-positive (Pα(+)S) and PDGFRA-negative (Pα(-)S) MSCs populations (Fig
1A), after infection with rKSHV.219 [40] the sorted populations were cultured in mesenchy-
mal stem cell maintenance media (MSC-media). We monitored KSHV infection by examining
the expression of a GFP cassette in the viral genome, and KSHV lytic infection through expres-
sion of RFP under the lytic viral PAN promoter. 72 hours post infection (hpi), we added puro-
mycin to select for infected cells. Using this method, we successfully generated mouse bone
marrow-derived MSC latently infected with KSHV (K-Pα(-)S and K-Pα (+)S) (Fig 1B). After
several passages, these latently infected cultures continued to express GFP and the KSHV pro-
tein LANA, indicating the establishment of latent KSHV persistent infection (Fig 1C). Impor-
tantly, we did not detect RFP expression in either infected cell lines indicating stable KSHV
latency. To study KSHV oncogenesis in these cells, we performed tumorigenic analysis and
found that KSHV-uninfected and KSHV-infected cell populations that were PDGFRA-positive
or PDGFRA-negative did not form tumors when subcutaneously injected in nude mice (S1
Fig).
The cellular mechanisms promoting inflammation, wound repair and angiogenesis, may
promote the development of KS tumors in KSHV-infected individuals. To test the effect of a
pro-angiogenic KS-like environment on KSHV tumorigenesis, we infected mouse bone mar-
row-derived PDGFRA-positive (Pα(+)S) and PDGFRA-negative (Pα(-)S) MSCs with
rKSHV.219. We then incubated the cells in KS-like media (K-Pα(+)S KS), a media that is rich
in heparin and endothelial cell growth factors (ECGF), which reproduces a pro-angiogenic/
vasculogenic environment in the culture [41, 42]. The percentage of KSHV de novo infection
was similar (80%) in both MSC and KS condition as well as in PDGFRA-negative and
PDGFRA-positive cells (S2 Fig). After two weeks of puromycin selection, we obtained KSHV-
infected PDGFRA-negative (K-Pα(-)S KS) or PDGFRA-positive MSCs growing in KS-like
media (K-Pα(+)S KS). We compared KSHV gene expression in K-Pα(-)S and K-Pα(+)S grow-
ing in KS-like media with those maintained and selected in MSC media. Interestingly, we
found upregulation of KSHV latent and lytic genes (LANA, RTA, vGPCR, and vIRF1) only in
K-Pα(+)S cells propagated in KS-like culture conditions (Fig 1D), indicating that this cell line-
age and environmental conditions favor KSHV gene expression in vitro.
KSHV infection is tumorigenic only in PDGFRA-positive MSCs (Pα(+)S)
grown in pro-angiogenic KS-like environmental conditions
Since we showed that pro-angiogenic KS-like culture conditions favor KSHV gene expression
in vitro (Fig 1D) including many viral lytic oncogenes, we determined whether these condi-
tions also conferred malignant cell characteristics to KSHV-infected Pα(+)S MSCs, such as
anchorage-independent cell growth in a soft-agar colony formation assay. Uninfected
PDGFRA-positive MSCs cultured in KS-like media and KSHV-infected PDGFRA-positive
MSCs cultured in MSC media did not grow on soft-agar (Fig 1E). In contrast, KSHV-infected
PDGFRA-positive (Pα(+)S) MSCs cultured in pro-angiogenic KS-like conditions (K-Pα(+)S
KS) were the only cells to form colonies in soft agar (Fig 1E), suggesting that the KS-like cul-
ture conditions conferred malignant phenotypic characteristics to K-Pα(+)S MSCs. More
importantly, subcutaneous injection of K-Pα(+)S KS cells into nude mice resulted in tumor
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formation in all 6 injected mice by 7 weeks. No tumors formed from either uninfected Pα(+)S
MSC growing in KS-like culture conditions or in infected Pα(+)S growing in MSC culture
conditions (Fig 1F). Paraffin-embedded sections of KSHV-infected PDGFRA-positive MSCs
tumors (K-Pα(+)S KS tumor) stained with hematoxylin and eosin (H&E) were analyzed by a
pathologist in a blind manner, confirming that these tumors were indistinguishable from the
vascularized spindle cell sarcomas formed by mECK36 tumors previously generated by our
lab, which were thoroughly characterized as KS-like tumors [26] (Fig 1G). Using immunofluo-
rescence detection of the KSHV LANA protein, we confirmed that the majority of the tumor
cells display the classic punctate nuclear staining (Fig 1H). Additionally, using the endothelial
cell marker PECAM1, we observed that these tumors displayed phenotypic markers that corre-
sponded to those typically found in human KS lesions (Fig 1I). We concluded that KSHV
infection of PDGFRA-positive MSCs in combination with a pro-angiogenic KS-like environ-
mental condition induces a malignant transformed phenotype in these cells, leading to tumori-
genicity in nude mice.
Upregulation of KSHV lytic gene expression during in vivo tumorigenesis
We have previously shown that KSHV tumorigenesis in the mECK36 mouse KS-like model
occurs with concomitant up-regulation of KSHV lytic genes and angiogenic ligands/receptors
[14, 26]. This KSHV in vivo lytic switch is thus responsible for the activation of many autocrine
and paracrine oncogenic signaling cascades, including the recently reported ligand-mediated
activation of PDGFRA signaling pathway that drives KS tumorigenesis [14]. RNA-sequencing
(RNA-seq) analysis of KSHV gene expression in tumors derived from KSHV-infected
PDGFRA-positive MSCs grown in KS-like media (K-Pα(+)S KS tumors), which were found to
be histologically indistinguishable from mECK36, also showed upregulation of KSHV lytic
gene expression compared to the tumorigenic cells grown in vitro (KSHV in vivo lytic switch)
(Fig 2A). We also compared the KSHV transcriptomes of our infected cells and tumors with
those obtained from published RNA-seq analysis of actual Kaposi’s Sarcoma human biopsies
[43] from AIDS-KS patients (Fig 2B and 2C). As shown in Fig 2B, the unsupervised hierarchi-
cal clustering analysis show that human KS samples cluster between the lytic-expressing
mouse KS-like tumors and the latently infected K-Pα(+)S KS cells. This shows that the KSHV
transcriptomes of MSCs grown in KS-like conditions are closer to those of actual human KS
tumors than those grown in MSC conditions. They also show that the transcriptomes of the
MSCs tumors are representative of some human KS samples as we previously reported for the
mECK36 model [26]. In fact, some human KS samples showed upregulation of KSHV lytic
genes when compared with the latently infected mouse MSCs grown in either MSC or KS-like
conditions, further supporting the relevance of KSHV in vivo lytic gene expression observed in
MSCs tumors (the in vivo lytic switch) to actual cases of human AIDS-KS. The upregulation of
Fig 1. KSHV infection is only tumorigenic in infected MSC PDGFRA-positive lineage grown in pro-angiogenic KS-like environment. A) Mouse
bone marrow-derived mesenchymal stem cells were stained for PDGFRA (Pα) and SCA-1 (S) expression. Mouse MSC Sca-1-positive, PDGFRA-
positive (Pα(+)S) and negative (Pα(-)S) populations were sorted by flow cytometry. B) PDGFRA-positive (Pα(+)S) and PDGFRA-negative (Pα(-)S)
MSCs were latently infected with rKSHV.219 and analyzed for GFP expression using a fluorescence microscope. C) Immunofluorescence analysis of
KSHV-infected Pα(+)S (K- Pα(+)S) and Pα(-)S (K- Pα(-)S) to evaluate KSHV LANA expression (red), nuclei were counterstained with DAPI (blue).
D) Fold-changes in KSHV gene expression between 24 hours KSHV post-infection and after KSHV latency establishment in MSC or KS-like media as
determined by RT-qPCR. Triplicates are shown as means ± SD. K-Pα(-)S population on the top and K-Pα(+)S population on the bottom. �P< 0.05. E)
Soft agar colony formation assay to determine anchorage-independent cell growth in Pα(+)S KS, K-Pα(+)S MSC, and K-Pα(+)S KS cells. F) Kaplan-
Meier percent tumor-free survival curve from subcutaneous injection of Pα(+)S KS, K-Pα(+)S MSC, and K-Pα(+)S KS cells into nude mice. N = 6. G)
Representative microscopic histological section of mouse KS-like mECK36 tumor and K-Pα(+)S KS tumor stained with hematoxylin and eosin (H&E).
H) Immunofluorescence analysis of KSHV LANA (red) in K-Pα(+)S KS tumor, nuclei were counterstained with DAPI (blue). I) Immunofluorescence
analysis of PECAM1 (red) in K-Pα(+)S KS tumor, nuclei were counterstained with DAPI (blue).
https://doi.org/10.1371/journal.ppat.1008221.g001
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KSHV lytic genes in K-Pα(+)S KS tumors correlated with PDFGRA signaling activation (Fig
2D) and phospho-PDGFRA co-distributed with KSHV LANA (Fig 2E), further supporting
our investigated link between KSHV and PDGFRA activation in mouse-KS tumors [14]. Host
gene RNA-seq comparison of KSHV-infected PDGFRA-positive cells grown in KS-like media
(K-Pα(+)S KS) to their corresponding tumors in nude mice revealed 1,861 differentially
expressed genes (DEGs) (Fig 2F). The analysis of these DEGs using Gene Ontology (GO),
Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome databases, uncovered
major changes in pathways involving glycolysis, respiratory electron transport, NOTCH sig-
naling, TGFB signaling and antigen processing and presentation among the most up-regulated
pathways during KSHV in vivo lytic switch and tumorigenesis (Fig 2G). The results from these
bioinformatics assessments are consistent with prior biological studies on several KSHV lytic
genes and lytic conversions upon environmental conditions [13]. These data also agree with
the predictions from the analysis of a human KS-signature and newer RNA-sequencing studies
derived from differentially expressed genes between KS and normal skin, which predicted the
activation of several paracrine axes by upregulation of receptors and/or their ligands [2] and
changes in TGFB signaling and glucose metabolism [43] similar to those observed in our MSC
tumors.
A de-repressed KSHV epigenome allows for expression of oncogenic KSHV
genes in tumorigenic PDGFRA-positive MSCs growing in a KS-like
environment
To understand the differences in oncogenicity between KSHV-infected PDGFRA-positive
MSCs grown in MSC versus KS-like media (K-Pα(+)S KS versus K-Pα(+)S MSC); we analyzed
the pattern of KSHV viral gene expression using RNA-seq analysis (Fig 3A). The results from
this analysis were in line with the qRT-PCR results depicted in Fig 1D which showed increased
KSHV gene expression in cells grown in KS-like media (K-Pα(+)S KS), and also revealed an
overall increased expression of KSHV genes in these tumorigenic cells. Importantly, we veri-
fied that these differences in viral gene expression are not due to differences in viral DNA
copy number (S3 Fig). Many of these KSHV genes are well-characterized viral oncogenes
such as vGPCR (ORF74), K12, vIRF1 (ORFK9), vFLIP (ORF71), K15. Our data suggest that
PDGFRA-positive KSHV MSCs growing in a pro-angiogenic KS-like environment (K-Pα(+)S
KS) display a unique KSHV transcriptional profile that encompasses enhanced expression of
oncogenic KSHV genes, without KSHV completing its full viral lytic cycle (abortive lytic
state), which likely leads to KSHV-induced tumorigenicity.
Several studies indicate that histone modifications play a role in the epigenetic regulation of
KSHV gene expression [44, 45]. Activating histone modifications like H3K4me3 are enriched
in some activated loci while repressive histone modifications like H3K27me3 are widespread
across the KSHV viral genome [46–48]. We determined if the differences in KSHV viral gene
expression between non-tumorigenic K-Pα(+)S MSC and tumorigenic K-Pα(+)S KS cells
Fig 2. Upregulation of KSHV lytic gene expression during in vivo tumorigenesis. A) Genome-wide analysis of KSHV transcripts by RNA deep
sequencing, comparison of the transcription profiles of K-Pα(+)S KS cells (N = 3) and K-Pα(+)S KS tumors (N = 8) derived from these cells. Levels of
viral gene transcription were quantified in reads per kilobase of coding region per million total read numbers (RPKM) in the sample. The y-axis
represents the number of reads aligned to each nucleotide position and x-axis represents the KSHV genome position. B) Unsupervised hierarchical
clustering of KSHV transcriptome among K-Pα(+)S KS cells, K-Pα(+)S KS tumors and human KS tumors. The arrows indicate KSHV oncogenes. C)
Multidimensional scaling plot showing the distance of each sample from each other determined by their KSHV expression profiles. D) Total and
phospho-PDGFRA were determined by immunoblotting in two MSC K-Pα(+)S KS tumors. Actin was used as a loading control. E) Immunofluorescence
analysis of K-Pα(+)S KS tumors to detect KSHV LANA (red) and phospho-PDGFRA (green). Cell nuclei were counterstained with DAPI (blue). F)
Volcano plot showing 1,861 differentially expressed genes (DEGs) analyzed by RNA-Seq between K-Pα(+)S KS tumors in vivo and K-Pα(+)S KS cells in
vitro. G) Functional enrichment analysis based on genes differentially expressed among K-Pα(+)S KS tumors and K-Pα(+)S KS cells.
https://doi.org/10.1371/journal.ppat.1008221.g002
PDGFRA defines MSC Kaposi’s sarcoma progenitors by enabling KSHV oncogenesis in angiogenic milieu
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008221 December 27, 2019 8 / 38
PDGFRA defines MSC Kaposi’s sarcoma progenitors by enabling KSHV oncogenesis in angiogenic milieu
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008221 December 27, 2019 9 / 38
could be attributed to differential epigenetic regulation at the viral promoters. We performed
chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) in three
biological replicates to map the distribution of two histone modifications, H3K4me3, and
H3K27me3, that are enriched at actively transcribed and repressed genes, respectively [49].
We found that KSHV chromatin contained both H3K4me3 and H3K27me3 marks; however,
with distinct patterns of association at KSHV genomic regions between K-Pα(+)S KS versus
K-Pα(+)S MSC cells (Fig 3A). As previously reported, the latency-associated locus where
KSHV genes that are constitutively expressed during latency are located, was enriched with
H3K4me3 in both K-Pα(+)S KS and K-Pα(+)S MSC cells (Fig 3A) [46, 48]. Interestingly,
H3K27me3 was widely distributed throughout the KSHV genome in both cells populations,
but this repressive mark was more enriched in the KSHV genome in non-tumorigenic K-Pα
(+)S MSC cells. This result correlates with the less KSHV gene expression observed in these
cells by qRT-PCR and RNA-seq. On the other hand and in agreement with the KSHV gene
expression upregulation seen in tumorigenic K-Pα(+)S KS cells, we observed more H3K4me3
activating marks on the KSHV genome of these tumorigenic cells, especially in immediate
early and early lytic genes (Fig 3A).
To delineate the characteristics of the chromatin structures associated with the regulatory
regions of KSHV genes, we aligned the KSHV open reading frames (ORFs) relative to their
translational start sites (TSS). We plotted the signal intensities of probes derived from the
ChIP-Seq analysis across a 2 kb region spanning 1 kb on either side of the TSS (please see
Materials and Methods for details) [46] (Fig 3B). Since RTA is responsible for the switch
between latency and lytic replication, its promoter is not only tightly repressed during latency,
but its silencing should also be rapidly reversible upon reactivation. We found that the RTA
promoter is enriched in both H3K4me3 and H3K27me3 during latency (Fig 3A and 3B), sug-
gesting it possesses a bivalent chromatin that maintains repression of the RTA promoter while
keeping it poised for rapid activation, in agreement with what was previously reported using
BCLBC-1, TRExBCBL1-RTA and SLK cells [46, 47]. Moreover, in K-Pα(+)S KS cells the RTA
promoter and other immediately early and early lytic promoters showed more activating
marks than in K-Pα(+)S MSC cells. These results point to epigenetic regulation as a contribu-
tory mechanism for the unique KSHV transcriptional program shown by K-Pα(+)S KS tumor-
igenic cells in vitro and support our MSC mouse model for studying the connection between
epigenetic regulation of KSHV gene expression and oncogenesis.
Global gene expression profiling and histone mark distribution in K-Pα(+)
S KS and K-Pα(+)S MSC cells
We showed that KSHV gene expression differences between non-tumorigenic K-Pα(+)S MSC
and tumorigenic K-Pα(+)S KS cells are explained at least, in part, by differences in epigenetic
regulation of the KSHV genome. In order to compare KSHV with host gene expression
Fig 3. A de-repressed KSHV epigenome allows for expression of oncogenic KSHV genes in tumorigenic PDGFRA-positive MSCs growing
in KS-like environment. A) Genome-wide analysis of KSHV transcripts by RNA deep sequencing, comparison of the transcription profiles of
MSC K-Pα(+)S MSC and K-Pα(+)S KS cells. Transcriptional levels for viral genes were quantified in reads per kilobase of coding region per
million total read numbers (RPKM) in the sample. The y-axis represents the number of reads aligned to each nucleotide position and x-axis
represents the KSHV genome position. Global patterns of H3K4 tri-methylation (H3K4me3) and H3K27 tri-methylation (H3K27me3) in K-Pα
(+)S MSC and K-Pα(+)S KS cells were analyzed by ChIP-seq assays as described in the text. Values shown on the y-axis represent the relative
enrichment of normalized signals from the immunoprecipitated material over input. B) Heat map representation of changes in histone
modifications at the gene regulatory regions of KSHV genes grouped by expression class Latent, Immediate-early lytic, Early lytic and Late lytic
genes. The rows display the relative abundance of the indicated histone modification within the −1 kb to +1 kb genomic regions flanking the
translational start site (TSS) of each viral gene. The blue and yellow colors denote lower-than-average and higher-than-average enrichment,
respectively.
https://doi.org/10.1371/journal.ppat.1008221.g003
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regulation in these two cell lines, we carried out a global gene expression profile by RNA-seq
analysis. We found more than 450 differentially expressed host genes (DEGs) between tumori-
genic K-Pα(+)S KS and non-tumorigenic K-Pα(+)S MSC cells (Fig 4A). These DEGs were
enriched for multiple biological processes; notably, PDGFR signaling, PI3K-AKT and p53 sig-
naling, together with cell cycle regulation (Fig 4B). Moreover, and as we showed for KSHV
gene expression (Fig 3), H3K27me3 and H3K4me3 ChIP-seq revealed slightly more H3K4me3
enrichment (Fig 4C) and fewer H3K27me3 (Fig 4D) at the promoters of these upregulated
genes in tumorigenic K-Pα(+)S KS cells, further confirming epigenetic regulation of transcrip-
tion at these loci.
Interestingly, Chip-seq analysis for the distribution of the two histone modifications,
H3K4me3 and H3K27me3, over the host genome revealed that K-Pα(+)S MSC cells displayed
more global enrichment of H3K27me3 at host genes compared with K-Pα(+)S KS cells, sug-
gesting that the host genome of K-Pα(+)S MSC cells is more transcriptionally repressed
genome-wide (Fig 4E). To characterize these repressed genes, we associated H3K27me3 ChIP-
seq peaks to all the genes of the mouse genome. We found that while the number of genes dec-
orated with H3K27me3 in the two K-Pα(+)S cells were comparable (9,696 in KSHV KS cells
versus 9,371 in K-Pα(+)S MSC cells) with a large number of genes common between the two
(8,158 genes decorated with H3K27me3 in both), 1,538 genes were exclusive to K-Pα(+)S KS
cells while 1,213 were exclusive to K-Pα(+)S MSC cells (Fig 4F). KEGG and REACTOME
pathway enrichment analysis was performed for these repressed H3K27me3 gene targets that
are specific to K-Pα(+)S KS or K-Pα(+)S MSC. In K-Pα(+)S MSC cells the most repressed
genes involved NOTCH1 regulation, signaling by NOTCH1 in Cancer, VEGFA-VEGFR2
pathway, TGFBR1/2 KD mutants in cancer, VEGFR2-mediated cell proliferation, signaling by
VEGF and p53 signaling pathways (Fig 4G). These aforementioned genes all related to KS and
KSHV oncogenic signaling, which thus, appear more de-repressed in the oncogenic K-Pα(+)S
KS cells. Interestingly, in the K-Pα(+)S KS cells, the most repressed genes involved Toll-Like
Receptor 4 cascade, Activated TLR4 signaling, Toll-like receptor signaling pathway, ZBP1-me-
diated induction of type 1 IFNs and RIG-1/MDA5 induction of IFN pathways, all related to
the innate immune response (Fig 4G and 4H) and the Type I IFN (IFNα and β) anti-viral
response. This suggests that the IFN anti-viral response would be more repressed in KSHV-
infected cells grown in a KS-like environment. In fact, K-Pα(+)S MSC cells showed higher
expression of IFNβ mRNA than K-Pα(+)S KS cells confirming the repression of the IFNβ loci
in K-Pα(+)S KS cells (Fig 4I). Moreover, we found that only K-Pα(+)S MSC cells upregulated
IFNβ expression after KSHV lytic reactivation with an HDAC inhibitor (SAHA/ Vorinostat)
(Fig 4I). Taken together our RNA-seq and ChIP-seq analysis on host and KSHV genes indi-
cates that tumorigenic K-Pα(+)S KS cells are more adapted to withstand oncogenic KSHV
lytic gene expression possibly by regulating PDGFR, PI3K-AKT, p53 and cell cycle pathways,
but also by repressing innate immune response genes upon induction of the lytic replication
program.
A permissive epigenetic landscape induced by a pro-angiogenic
environment promotes an oncogenic viral lytic-driven mechanism of
tumorigenesis
Our results suggest that KSHV and host epigenetic mechanisms which regulate KSHV lytic
gene expression dictate at least, in part, the differences in tumorigenicity between cells grown
in MSC and KS media. Fig 2A shows that K-Pα(+)S KS tumorigenicity occurs along with a
steep increase in KSHV lytic gene expression (KSHV in vivo lytic switch). In order to model
the biological consequences of this tumorigenic lytic switch in K-Pα(+)S KS and K-Pα(+)S
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MSC cells in an in vitro system, we used HDAC inhibitors (HDACi) such as SAHA/ Vorino-
stat which we and others have shown are powerful inducers of KSHV lytic replication in sev-
eral systems [50–53]. We found that K-Pα(+)S MSC cells, which are not tumorigenic,
massively upregulated KSHV lytic genes (100-folds) after 24 hours of SAHA treatment, as
shown using qRT-PCR (Fig 5A). In contrast, in tumorigenic K-Pα(+)S KS cells that display a
higher level of basal KSHV lytic gene expression, the fold-increase expression of KSHV lytic
genes after reactivation was an order of magnitude lower than in K-Pα(+)S MSC cells (Fig
5A). We found that KSHV reactivation following SAHA treatment induces the appearance of
a RFP (early lytic marker) positive cell population in both K-Pα(+)S MSC (up to 10%) and
K-Pα(+)S KS (up to 3%) cells (Fig 5B). To characterize the pattern of KSHV gene expression
in GFP-positive and RFP-positive cell populations generated after reactivation, we used fluo-
rescence-activated cell sorting (FACS) to separate these two populations. We found that the
RFP positive populations of both K-Pα(+)S MSC and K-Pα(+)S KS cells (Fig 5C, left panel)
showed massive upregulation of KSHV lytic and latent genes, when compared to un-induced
cells, characteristic of lytic induction. The GFP-positive/RFP-negative population from the
non-tumorigenic K-Pα(+)S MSC cells also showed upregulation of both KSHV latent and lytic
genes (LANA, vFLIP and vCyclin, RTA, vGCPR, K8.1) after SAHA treatment, suggesting
KSHV lytic reactivation (Fig 5C, right panel) in this population as well. On the other hand, the
GFP-positive/RFP-negative population from the tumorigenic K-Pα(+)S KS cells showed only
upregulation of some specific lytic genes (RTA and K8.1) (Fig 5C, right panel). Thus, the RFP-
lytic marker distribution allowed us to identify a population of “classic” lytically induced cells
that are similar in both K-Pα(+)S MSC and K-Pα(+)S KS cells. Interestingly, the GFP-positive/
RFP-negative population, which corresponds to the vast majority of the cells, shows a distinct
pattern of KSHV gene expression between K-Pα(+)S MSC and K-Pα(+)S KS cells after KSHV
lytic reactivation. These results suggest that differences in the epigenetic environment induced
by KS-like culture conditions can lead to a different outcome for lytic reactivation in K-Pα(+)S
KS cells and more importantly, be a key determinant for the oncogenic consequences of the
KSHV lytic switch.
To determine if differences in the culture conditions can affect the proliferation of infected
cells upon the lytic switch, we used an IncuCyte Live-Cell Imaging and Analysis System, which
enables real-time, automated cell proliferation assays to follow the growth of RFP-positive and
GFP-positive populations among SAHA-induced cells. K-Pα(+)S MSC and K-Pα(+)S KS
RFP-positive populations, which we found, do not differ in their pattern of KSHV induction
(Fig 5D, left panel), augment in cell number upon lytic induction, then reach a limit of cell
growth. In contrast, in the case of GFP-positive cells, we found that the K-Pα(+)S MSC cells
stop proliferating after reactivation (Fig 5D, right panel), while induced K-Pα(+)S KS cells
continue to proliferate. Interestingly, Fig 5C shows that both cells display KSHV lytic gene
expression, but only the tumorigenic K-Pα(+)S KS cells are able to continue proliferating in
spite of lytic KSHV gene expression. Moreover, K-Pα(+)S KS cells showed more proliferation
Fig 4. Global gene expression profiling and histone marks distribution in K-Pα(+)S KS and K-Pα(+)S MSCs. A) Volcano plot showing 454
differentially expressed genes (DEGs) analyzed by RNA-seq between K-Pα(+)S MSC and K-Pα(+)S KS cells. B) Functional enrichment analysis based
on genes differentially expressed among K-Pα(+)S MSC and K-Pα(+)S KS cells. C) H3K4me3 ChIP-seq signals on DEGs in K-Pα(+)S MSC and K-Pα
(+)S KS cells. D) H3K27me3 ChIP-seq signals on DEGs in K-Pα(+)S MSC and K-Pα(+)S KS cells. E) H3K4me3 (left) and H3K27me3 (right) ChIP-seq
signals in K-Pα(+)S MSC and K-Pα(+)S KS cells. F) Venn diagrams showing the overlap between H3K27me3-enriched genes in K-Pα(+)S MSC and
K-Pα(+)S KS cells. G) Pathway analysis representing KEGG and REACTOME pathway enriched by the genes with differentially enriched regions
(DERs) of H3K27me3 and H3K4me3 in K-Pα(+)S MSC (bottom) and K-Pα(+)S KS (top) cells. H) Genome browser screenshots of H3K27me3 ChIP-
seq signal in K-Pα(+)S MSC and K-Pα(+)S KS cells at the IFNβ genomic region. I) Fold-changes of IFNβ gene expression in K-Pα(+)S MSC and K-Pα
(+)S KS cells before and after KSHV lytic reactivation, determined by RT-qPCR. Triplicates are shown as means ± SD. �P< 0.05.
https://doi.org/10.1371/journal.ppat.1008221.g004
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markers (such as Ki67) than K-Pα(+)S MSC cells (Fig 5E) after 72hs of KSHV lytic
reactivation.
Cell cycle arrest and cellular senescence are known to occur during the lytic replication
phase of herpesviruses and other DNA viruses [54]. This type of senescence, characterized by
the upregulation of cell cycle inhibitors such as p53 and p21, is generally also induced by aber-
rant proliferative signals of oncogenes such as activated Ras (RasV12) leading to increased oxi-
dative DNA damage [55, 56]. The increase in expression of many oncogenic KSHV genes
occurring during lytic replication could induce oncogenic stress that would typically be
expected to trigger oncogene-induced senescence (OIS) [57, 58]. A widely used assay for cell
senescence is the cytochemical detection of acidic β-galactosidase activity (pH 6.0), termed
senescence-associated β-galactosidase (SA-β-Gal) [59]. In order to fulfill all the hallmarks for
establishing cell senescence [60, 61] we measured 1) Markers for Inhibition of the cell cycle
and levels of cell cycle arrest proteins 2) Expression of acidic beta-galactosidase and 3) Upregu-
lation of Senescence Associated Secretory Phenotype (SASP) and other senescence markers in
K-Pα(+)S MSC and K-Pα(+)S KS cells after KSHV reactivation. As shown in Fig 5E–5H, K-Pα
(+)S MSC cells: 1) Displayed decreased levels of proliferation markers such as Ki67 and expres-
sion of cyclin D1 2) Displayed enhanced features and markers of cell senescence, such as
increased SA-β-Gal staining, and upregulation of SASP and senescence markers (IL-6,
IGFBP2, PAI-1), 3) Expressed cell cycle inhibitors such p53 and p21 that correlated with their
arrest of cellular proliferation and increase in the number of cells that underwent senescence.
On the other hand, tumorigenic K-Pα(+)S KS cells showed low SA-β-Gal staining, lower levels
of SASP and senescence markers, higher expression of Ki67 and upregulated cyclin D1, despite
upregulation of p21 and p53 after lytic reactivation, which correlated with their increase in
proliferation (Fig 5D–5H). Importantly, K-Pα(+)S MSC cells showed less DNA damage
response (such as ƴH2AX) (Fig 5I), compared to tumorigenic K-Pα(+)S KS cells after KSHV
reactivation. These tumorigenic cells display robust proliferation markers in spite of an
increased level of DNA repair foci, further indicating that these cells are able to overcome
KSHV-driven oncogene-induced senescence as well as DNA damage-induced cell cycle arrest,
continuing to proliferate after KSHV reactivation.
Fig 5. A permissive epigenetic landscape induced by a pro-angiogenic environment promotes an oncogenic viral lytic-driven mechanism of
tumorigenesis. A) Fold-changes of KSHV gene expression in K-Pα(+)S MSC and K-Pα(+)S KS cells after SAHA (7,5 uM) treatment for 24 hours,
determined by RT-qPCR. Triplicates fold change to un-induced K-Pα(+)S MSC are presented as means ± SD. �P< 0.05. B) Percentage of RFP-positive and
GFP-positive cells after 72 hours of KSHV reactivation measured by Flow cytometry in K-Pα(+)S MSC and K-Pα(+)S KS cells. C) Left panel, fold-changes
of KSHV gene expression in sorted RFP-positive population of K-Pα(+)S MSC and K-Pα(+)S KS cells after 72 hours of SAHA treatment were determined
by RT-qPCR. Triplicates fold change to un-induced K-Pα(+)S MSC are presented as means ± SD. �P< 0.05. The heatmap for the mean RT-qPCR data is
shown below. Right panel, fold-changes of KSHV gene expression in sorted GFP-positive population in K-Pα(+)S MSC and K-Pα(+)S KS cells after 72
hours of SAHA treatment were determined by RT-qPCR. Triplicates fold change to un-induced K-Pα(+)S MSC are presented as means ± SD. �P< 0.05.
The heatmap for the mean RT-qPCR data is shown below. D) K-Pα(+)S MSC and K-Pα(+)S KS cells were treated with SAHA and incubated in an Incucyte
Zoom (Essen Bioscience), acquiring red and green fluorescence images. The cell proliferation graphs of RFP-positive (left panel) and GFP-positive (right
panel) cells were graphed over time as a measure of proliferation and shown as mean ± SE from three replicates for each condition. E) Immunofluorescence
analysis of Ki67 expression (red) was performed after 72 hours of SAHA treatment on GFP-positive K-Pα(+)S MSC and GFP-positive K-Pα(+)S KS cells;
nuclei were counterstained with DAPI (blue).The quantification is shown at the right of the images. Values are presented as means ± SD. �P< 0.05. F) SA β-
gal staining was performed after 72 hours of SAHA treatment on K-Pα(+)S MSC and K-Pα(+)S KS cells. The quantification is shown at the right of
corresponding panels. Values are presented as means ± SD. �P< 0.05. G) mRNA fold-changes of markers of senescence and SASP or Senescence
Associated Secretory Phenotype in K-Pα(+)S MSC and K-Pα(+)S KS after 72 hours of SAHA treatment were assessed by RT-qPCR in triplicate and are
presented as means ± SD. �P<0.05. H) p53, p21, and Cyclin D1 levels were analyzed by immunoblotting in K-Pα(+)S MSC and K-Pα(+)S KS cells after 72
hours of SAHA treatment. Histone 3 K27 Acetylation (H3K27Ac) was used as the control for HDAC inhibition by SAHA. Actin was used as loading
control. I) Immunofluorescence analysis of ƴH2AX expression (red) was performed after 72 hours of SAHA treatment on GFP-positive K-Pα(+)S MSC and
GFP-positive K-Pα(+)S KS cells; nuclei were counterstained with DAPI (blue). The quantification is shown at the right of the images. Values are presented
as means ± SD. �P< 0.05. J) Spectrum In Vivo Imaging System (IVIS) of Matrigel-plugs (1 week after injection) containing GFP-positive PDGFRA-positive
MSCs from K-Pα(+)S MSC and K-Pα(+)S KS cells. Black Squares indicate site of injection. K) Fold-changes of KSHV gene expression in K-Pα(+)S MSC
and K-Pα(+)S KS after 1 week in vivo Matrigel-plug were assessed by RT-qPCR in triplicate and are presented as means ± SD.
https://doi.org/10.1371/journal.ppat.1008221.g005
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In order to study the consequences of the in vivo KSHV lytic switch in more physiological
conditions, we performed a short-term in vivo Matrigel-plug experiment with K-Pα(+)S MSC
and K-Pα(+)S KS cells. Within the Matrigel-plug, the cells were subjected to in vivo growth
conditions for a period of one week. We injected K-Pα(+)S MSC and K-Pα(+)S KS cells subcu-
taneously into Matrigel in nude mice, and after one week of in vivo growth, we analyzed the
growth of viable cells by the GFP-expression using Spectrum In Vivo Imaging System (IVIS).
We also extracted the Matrigel-plug containing cells to document the in vivo KSHV gene
expression lytic switch by qRT-PCR. After one week of in vivo growth, K-Pα(+)S KS cells con-
tinued proliferating, as shown by the GFP-positive signal at the site of injection, however,
K-Pα(+)S MSC cells were not able to proliferate in vivo, as seen by the lack of GFP signal (Fig
5J). Real time qRT-PCR analysis showed that both cell lines displayed upregulation of KSHV
lytic genes (Fig 5K); yet, only tumorigenic K-Pα(+)S KS cells were able to proliferate in the
context of the KSHV in vivo lytic switch. On the other hand, the growth inhibition shown by
K-Pα(+)S MSC cells directly occurred together with the upregulation of KSHV gene expres-
sion in vivo (Fig 5K). The results obtained with this Matrigel-plug in in vivo experiments
mimic those observed with KSHV lytic induction in vitro (Fig 5D). Taken together, these in
vitro and in vivo results demonstrate that PDGFRA-positive KSHV-infected MSCs are able to
proliferate in vitro and in vivo in the presence of KSHV oncogenic gene expression only when
they are subjected to a pro-angiogenic KS-like environment. Thus, these conditions not only
conferred an epigenetic adaptation leading to increased KSHV gene expression but also should
confer a mechanism, which upon in vivo lytic switch, will allow them to overcome KSHV-
driven oncogene-induced senescence and cell cycle arrest, leading to tumorigenesis.
PDGFRA signaling allows KSHV-infected PDGFRA-positive MSCs grown
in a KS-like environment to continue proliferating after lytic reactivation
We sought to elucidate the mechanism that allows K-Pα(+)S KS cells to continue proliferating
after KSHV lytic reactivation. To test, in an unbiased manner, which tyrosine kinase receptors
were differentially activated between K-Pα(+)S MSC and K-Pα(+)S KS cells after lytic reactiva-
tion, we used a tyrosine kinase proteomic array (Fig 6A). We found that PDGFRA was the
most differentially activated tyrosine kinase over 39 RTKs tested in the array (Fig 6A). This
finding was consistent with the pathway enrichment analysis shown in Fig 4B, K-Pα(+)S cells
grown in KS-like media display enhanced expression of a genetic network enriched in genes
that regulate PDGFR signaling, AKT and cell cycle. To characterize the involvement of
PDGFRA activation and downstream signaling pathways, we analyzed the cells after KSHV
lytic reactivation for PDGFRA and AKT signaling activation. K-Pα(+)S KS cells showed acti-
vation of both PDGFRA and AKT signaling compared to K-Pα(+)S MSC cells (Fig 6B). More-
over, we found that activation of PDGFRA signaling in induced K-Pα(+)S KS cells correlated
with upregulation of its ligands PDGFA and PDGFB (Fig 6C), further confirming the fact that
KSHV lytic expression induces ligand-mediated activation of this oncogenic driver [14]. This
KSHV-induced ligand-mediated activation of PDGFRA signaling could constitute an impor-
tant mechanism mediating the adaptation of the K-Pα(+)S KS cells to continue proliferating
after lytic reactivation.
PDGFRA signaling is a critical pathway to overcome KSHV-driven
oncogene-induced senescence and for the proliferation of infected cells
To test whether or not the PDGFRA activation, which is prominent in lytically-induced K-Pα
(+)S KS cells but not in K-Pα(+)S MSC cells, is necessary for enabling cell proliferation upon
KSHV lytic reactivation, we inhibited this pathway using a highly selective PDGFR tyrosine
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kinase inhibitor (PDGFR Tyrosine Kinase Inhibitor IV, IC50: PDGFR-α: IC50 = 45 nM;
PDGFR-β: IC50 = 4.2 nM; c-Abl: IC50 = 22 nM; c-Src: IC50 = 185 nM; VEGFR: IC50 = 3.1 μM;
bFGFR-1: IC50 = 45.8 μM; EGFR: IC50 =>100 μM). We found that in the presence of the
PDGFR tyrosine kinase inhibitor K-Pα(+)S KS cells were not able to continue proliferating
upon lytic reactivation (Fig 6E). Importantly, the same concentration of inhibitor was unable to
halt proliferation of K-Pα(+)S KS cells that had not been lytically induced (Fig 6D). Moreover,
upon lytic reactivation, inhibition of PDGFRA activation correlated with decreased levels of the
proliferation marker Ki67 (Fig 6F) and with increased levels of senescence, SA-β-Gal staining
(Fig 6G). Molecular analysis showed that the inhibition of PDGFRA signaling leads to a down-
regulation of Cyclin D1 and the PDGFRA ligands, PDGFA and PDGFB (Fig 6H). Taken
together, our data indicate that activation of PDGFR signaling during KSHV lytic reactivation
plays a role in allowing the proliferation of infected cells. These data, implicate this pathway as
essential for overcoming KSHV-driven oncogene-induced senescence and for promoting
KSHV-infected cell survival and proliferation, thus allowing KSHV tumorigenesis to progress.
MSC culture conditions favor viral production in KSHV-infected human
MSCs, while pro-angiogenic KS-like culture conditions are permissive for
PDGFRA signaling-mediated proliferation of infected cells
To validate our results of KSHV infection with murine MSCs in a relevant human infection
system, we studied the effect of different culture conditions in KSHV-infected human MSCs
that were shown to be bona-fide human cell targets of KSHV infection [35–38]. Bone marrow-
derived Human MSCs were infected with rKSHV219 (K-hMSC) and subsequently cultured in
either MSC media (K-hMSC MSC) or in KS-like pro-angiogenic conditions (K-hMSC KS).
We monitored the ratios of latent to lytic KSHV infection by GFP and RFP expression using
fluorescence microscopy as well as by quantifying the percentage of GFP versus RFP-positive
cells by Flow Cytometry analysis (Fig 7A–7C). We observed that in contrast to mouse MSCs
and regardless of the culture conditions, infected human MSCs showed both KSHV latently
and lytically infected cells (Fig 7A). K-hMSC growing in KS-like media displayed lower per-
centages of RFP-positive cells than KSHV-infected hMSCs growing in MSC media (Fig 7A
and Fig 7C). Since hMSCs have been shown to be permissive for KSHV productive replication
[35], we quantified the production of infectious virions by infecting HEK AD-293 cells. We
found that K-hMSCs grown in MSC media produced more virions than those grown in KS-
like conditions (20% vs 5% of infected HEK AD-293) (Fig 7D). Quantification of KSHV DNA
content in the supernatants of the cultures showed that K-hMSC MSC contained more KSHV
genomes/mL than K-hMSC KS, which correlated with the higher infectious virions content of
Fig 6. PDGFRA signaling allows KSHV-infected PDGFRA-positive MSCs grown in KS-like environment to continue proliferating after lytic
reactivation. A) Mouse Phospho-Receptor Tyrosine Kinase (RTK) Array Kit used to quantify levels of phosphorylation of 39 RTKs in K-Pα(+)S MSC
and K-Pα(+)S KS cells after 72 hours of SAHA treatment pointing to major activation spot corresponding to PDGF receptor alpha chain. B) Total and
phospho-PDGFRA together with Total and phospho-AKT levels were analyzed by immunoblotting in K-Pα(+)S MSC and K-Pα(+)S KS cells after 72
hours of SAHA treatment. C) PDGFA and PDGFB levels were analyzed by immunoblotting in K-Pα(+)S MSC and K-Pα(+)S KS cells after 72 hours of
SAHA treatment. Actin was used as loading control. D) K-Pα(+)S KS cells were treated with 0.1uM of PDGFR tyrosine kinase inhibitor IV or left
untreated, and incubated in an Incucyte Zoom (Essen Bioscience) to acquire green fluorescence images. The proliferation graph is shown the
mean ± SE from three replicates for each condition. E) K-Pα(+)S KS cells were treated with SAHA alone or in combination with 0.1μM of PDGFR
tyrosine kinase inhibitor IV, and incubated in an Incucyte Zoom (Essen Bioscience) to acquire green fluorescence images. The proliferation graph is
shown the mean ± SE from three replicates for each condition. F) Immunofluorescence analysis of Ki67 expression (red) in K-Pα(+)S KS cells treated
with SAHA alone or in combination with 0.1 μM of PDGFR tyrosine kinase inhibitor IV for 72 hours, nuclei were counterstained with DAPI (blue).
Infected cells are GFP-positive. G) SA β-gal staining was performed after 72 hours of SAHA plus 0.1 μM of PDGFR tyrosine kinase inhibitor IV
treatment of K-Pα(+)S KS cells. H) Total and phospho-PDGFRA, Cyclin D1, PDGFA and PDGFB levels were determined by immunoblotting in K-Pα
(+)S KS cells treated with SAHA alone or in combination with 0.1 μM of PDGFR tyrosine kinase inhibitor IV for 72 hours. Actin was used as loading
control.
https://doi.org/10.1371/journal.ppat.1008221.g006
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the supernatants (Fig 7E). Paradoxically, the KSHV pattern and levels of viral gene expression
in K-hMSCs MSCs and KS were quite similar regardless of the culture conditions (Fig 7F),
suggesting that these culture conditions may be affecting the efficiency of virions production.
These results show that culture of K-hMSCs under different environmental conditions also
can lead to different outcomes for KSHV lytic replication.
Since in K-hMSC, KSHV productive lytic replication was spontaneous, we decided to use
this opportunity to compare the impact of KSHV lytic gene expression on the proliferation of
K-hMSCs growing in different culture conditions without having to resort to drug-based or
HDACi lytic reactivation. We used an IncuCyte1 Live-Cell Imaging and Analysis System to
follow the growth of RFP-positive and GFP-positive populations of K-hMSCs growing in MSC
or KS-like media. As observed for murine MSCs, the RFP-positive population of both K-
hMSC MSC and K-hMSC KS increased in numbers and reached a plateau of cell proliferation
(Fig 7G). Interestingly, as found in murine MSCs, the GFP-positive population of K-hMSC KS
continue to proliferate over time (Fig 7H) while the GFP-positive population of K-hMSC MSC
stopped proliferating shortly after KSHV infection (Fig 7H). We next sought to determine if
proliferation upon infection in KS-like media was a unique feature of PDGFRA expressing
KSHV targets such as hMSCs. We choose low passage primary human lymphatic endothelial
cells (hLECs) which are PDGFR-negative and were shown to be permissive for KSHV latent
and lytic infection [13, 62, 63]. Interestingly, LECs showed less lytic infection in KS media
than in their specific cell culture media, EGM2-MV, (Fig 7I and 7J bottom panels). Impor-
tantly, they were not able to continue proliferating after KSHV infection in any of the two cell
culture media (Fig 7J, top panel).
Seeking a molecular explanation for the unique ability of K-hMSC growing in KS-like con-
ditions to proliferate, and based on our results depicted in Figs 5 and 6 using mouse MSCs, we
evaluated cyclin D1 expression and PDGFRA activation in human lymphatic endothelial cells
and human mesenchymal stem cells infected with KSHV and exposed to the different media.
As shown in Fig 7K, proliferating K-hMSC growing in KS media showed much higher levels
Fig 7. MSC culture conditions favor viral production in KSHV-infected human MSCs, while KS-like culture conditions are permissive for
PDGFRA-mediated proliferation of infected cells. A) Human MSC KSHV infection was monitored by fluorescence microscopy using the GFP
reporter driven by the constitutive promoter of cellular EF-1 and the RFP reporter driven by the early lytic gene PAN promoter. B) GFP expression
analysis by flow cytometer in human MSCs after 96 hours of KSHV infection in MSC or KS-like media. The graph shown is from triplicates and
presented as means ± SD. C) RFP expression analysis by flow cytometer on human MSCs after 96 hours of KSHV infection in MSC or KS-like media.
The graph shown is from triplicates and presented as means ± SD. ��P< 0.05. D) Cell-free supernatants of rKSHV.219-infected human MSC were
used to de novo infect HEK AD293 cells. After 72 hours of infection, HEK AD293 GFP-positive cells were measured by flow Cytometry. The graph
shown is from triplicates and presented as means ± SD. ���P< 0.05. E) Bars represent mean percent copy number of viral DNA levels in cell-free
supernatants of human MSCs after 96 hours of KSHV infection in MSC or KS-like media determined by qPCR. The graph shown is from triplicates
and presented as means ± SD. �P< 0.05. F) Fold-changes in KSHV gene expression between mouse K-Pα(+)S MSC cells, K-hMSC MSC and K-hMSC
KS cells after 96 hours of KSHV de novo infection determined by RT-qPCR in triplicates and presented as means ± SD. G) Human MSCs were infected
with KSHV in MSC or KS-like media and incubated in an Incucyte Zoom (Essen Bioscience), acquiring red fluorescence images. The proliferation of
lytically infected cells (RFP-positive) is plotted over time. The graph shows the mean ± SE from three replicates for each condition. H) Human MSCs
were infected with KSHV in MSC or KS-like media and incubated in an Incucyte Zoom (Essen Bioscience), acquiring green fluorescence images. The
proliferation of latently infected cells (GFP-positive) is plotted over time. The graph shows the mean ± SE from three replicates for each condition. I)
Human LECs KSHV infection in EGM2-MV or KS-like media was monitored by fluorescence microscopy using the GFP reporter driven by the
constitutive promoter of cellular EF-1 and the RFP reporter driven by the early lytic gene PAN promoter. J) Human LECs were infected with KSHV in
EGM2-MV or KS-like media and incubated in an Incucyte Zoom (Essen Bioscience), acquiring red fluorescence images, top panel, and green
fluorescence images, bottom panel. The proliferation of lytically infected cells (RFP-positive, bottom panel) and latently infected cells (GFP-positive,
top panel) is plotted over time. The graph shows the mean ± SE from three replicates for each condition. K) Total and phospho-PDGFRA, Cyclin D1
and VEGFR3 levels were determined by immunoblotting in human MSCs and LECs after 96 hours of KSHV infection in MSC, EGM2-MV or KS-like
media. L) Human MSC cells were infected with KSHV in MSC or KS-like media and incubated in an Incucyte Zoom (Essen Bioscience) in the
presence of 0.1 μM PDGFR tyrosine kinase inhibitor IV, acquiring green fluorescence images. KSHV infection and proliferation of the GFP positive
cells is plotted over time. The graph shows the mean ± SE from three replicates for each condition. M) Total and phospho-PDGFRA levels were
determined by immunoblotting in human MSCs after 96 hours of KSHV infection in MSC or KS-like media in the presence of 0.1 μM PDGFR
tyrosine kinase inhibitor IV.
https://doi.org/10.1371/journal.ppat.1008221.g007
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of PDGFRA activation and Cyclin D1 expression than K-hMSC growing in MSC media. As
expected, LECs showed low levels of expression of Cyclin D1 and no expression of PDGFRA
after KSHV infection, which correlated with less cell proliferation. We employed VEGFR3 as a
specific lymphatic endothelial marker (Fig 7K). To determine whether the observed PDGFRA
signaling activation was necessary for enabling cell proliferation of K-hMSC KS, we measured
proliferation of K-hMSC MSC and K-hMSC KS in the presence or absence of a PDGFR tyro-
sine kinase inhibitor (PDGFR Tyrosine Kinase Inhibitor IV). We found that in both KSHV-
infected hMSCs grown in presence of the inhibitor, PDGFRA signaling was abolished and the
proliferation was inhibited shortly after infection (Fig 7L and 7M). This pattern of prolifera-
tion is reminiscent of K-hMSCs MSC, which were not substantially affected by the PDGFR
inhibitor. These results illustrate that, as shown for mouse MSCs, the outcome for KSHV
infection of human cells is strongly determined by the cell type and the culture conditions.
While lymphatic endothelial cells, in EGM2-MV and KS media, and mesenchymal stem cells
in MSC culture conditions favor viral production and do not proliferate, mesenchymal stem
cells infected in KS-like culture conditions are more permissive for enabling PDGFRA-medi-
ated proliferation of productively infected hMSC cultures.
Discussion
Human virally-induced cancers are mainly characterized by long incubation periods and the
fact that the majority of infected individuals do not develop cancer. This is due to the need for
specific host conditions and factors that are necessary to enable a full viral-mediated transfor-
mation [1]. The KS spindle-cell progenitor and specific host conditions of KSHV-driven onco-
genesis upon de novo infection are poorly understood. We identified PDGFRA(+)/SCA-1(+)
bone marrow-derived mesenchymal stem cells (Pα(+)S MSCs) as KS spindle-cell progenitors
and found that pro-angiogenic environmental conditions typical of KS, inflammation and
wound healing are critical for KSHV sarcomagenesis. This is because growth in KS-like condi-
tions generates a de-repressed KSHV epigenome allowing oncogenic KSHV gene expression
in infected Pα(+)S MSCs. Furthermore, these growth conditions allow KSHV-infected Pα(+)S
MSCs to overcome KSHV-driven oncogene-induced senescence and cell cycle arrest via a
PDGFRA-signaling mechanism; thus identifying PDGFRA not only as a phenotypic determi-
nant for KS-progenitors but also as a critical enabler for viral oncogenesis (Fig 8).
AIDS-KS lesions are characterized by proliferating KSHV-infected spindle cells, however,
the origin of the spindle cells (SCs) remains enigmatic because they express markers of multi-
ple cellular lineages, including endothelial, monocytic, and smooth muscle [6]. Initial immu-
nohistochemistry studies showed that KS SCs are poorly differentiated cells showing
phenotypic markers such as VEGFRs that suggest an endothelial origin, however, KSHV-
infected primary endothelial cells in culture do not outgrow their uninfected counterparts,
lose their KSHV genomes after extended passage in tissue culture, do not grow in soft agar and
do not form tumors in nude mice [64]. On the other hand telomerase-immortalized human
endothelial cell line infected with KSHV can become transformed and tumorigenic [24, 25].
Prior studies have suggested the role of mesenchymal stem cells (MSCs) as KSHV target and
KS progenitors [28, 34–38]. In fact several KS models made from primary bone marrow-
derived mouse endothelial lineage/adherent cells [26, 27] and one from rat MSCs [28] formed
tumors in a KSHV-dependent manner, suggesting that these populations contain cell types in
which KSHV infection is oncogenic. Sarcomas are cancers of mesenchymal origin [31], with
Platelet-derived growth factor receptor (PDGFR) signaling playing a significant part in mesen-
chymal biology, including mesenchymal stem cell differentiation, growth, and angiogenesis
[30]. Moreover, our recent studies showing that PDGFRA signaling is an oncogenic driver in
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KSHV sarcomagenesis and that it is consistently found in AIDS-KS tissue samples in its acti-
vated form [14], point to a bone marrow-derived PDGFRA(+) MSCs such as the Pα(+)S
MSCs, which our study now show is a cell progenitor target of KSHV-driven sarcomagenesis.
Clinical observations, such as the appearance of KS tumors in surgical scars or sites of
trauma (Koebner phenomenon) [65], suggest that cellular mechanisms such as inflammation,
wound repair and angiogenesis are necessary to promote KS tumorigenesis. We found that Pα
(+)S MSCs, which are recruited to sites of injury and inflammation [66], are highly permissive
to KSHV infection. More importantly, we found that this infection is only oncogenic when it
occurs in the context of a pro-angiogenic KS-like environment. These conditions favor
enhanced KSHV lytic gene expression in KSHV-infected Pα(+)S MSCs conferring malignant
Fig 8. PDGFRA defines the mesenchymal stem cell Kaposi’s sarcoma progenitors by enabling KSHV oncogenesis in an
angiogenic environment. Model showing PDGFRA(+)/SCA-1(+) bone marrow-derived mesenchymal stem cells (Pα(+)S
MSCs) as KS spindle-cell progenitors. Pro-angiogenic environmental conditions typical of KS (KS-like media), inflammation
and wound healing are critical for KSHV sarcomagenesis. This is because growth in KS-like conditions generates a de-
repressed KSHV epigenome allowing oncogenic KSHV gene expression in infected Pα(+)S MSCs. Furthermore, these
growth conditions allow KSHV-infected Pα(+)S MSCs to overcome KSHV-driven oncogene-induced senescence and cell
cycle arrest via a PDGFRA-signaling mechanism; thus identifying PDGFRA not only as a phenotypic determinant for KS-
progenitors but also as a critical enabler for viral oncogenesis.
https://doi.org/10.1371/journal.ppat.1008221.g008
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cell characteristics and tumorigenicity in nude mice (Fig 8). We previously found that
KSHVBac36 is angiogenic and tumorigenic in an endothelial cell lineage of adherent bone
marrow cell preparations [26], which prompted us to ‘target’ putative progenitors among this
transfected heterogeneous cell population. Our present study identified the KS progenitor cell
type in the bone marrow as the Pα(+)S MSCs, and demonstrated the need for pro-angiogenic
KS-like culture conditions for oncogenic viral gene expression and tumorigenesis (Fig 8).
To reproduce pro-angiogenic KS-like culture conditions we added to the cell culture media
crude preparations of endothelial cell growth factors (ECGF) [41, 42] together with heparin,
which was shown to potentiates the mitogenic activity of ECGF [67]. The main active compo-
nent of these crude extracts of ECGF is basic fibroblast growth factor (bFGF), which is a very
strong mitogen for endothelial cells in culture and an angiogenic growth factor [68, 69]. Sev-
eral lines of evidence suggest that KS is an angiogenic and inflammatory cytokine-mediated
driven disease; at least in early stages, and that angiogenic factors and; in particular, bFGF,
play a role in lesion development [70, 71]. Basic FGF is highly expressed at the RNA and pro-
tein level by cultured AIDS-KS cells and in spindle cells from AIDS-KS and classic KS tissue
[72, 73]. Moreover, in vitro studies have shown that a cooperation between PDGFB and bFGF
is responsible of inducing the expression of PDGFRA and FGFR1/2, promoting proliferation
of Pα(+)S MSCs without altering their multipotency or inducing their differentiation [74].
Our results point to the importance of these ECGFs as part of an angiogenic environment pro-
moting enhanced oncogenic KSHV gene expression leading to KSHV oncogenesis.
Tumors that arise from K-Pα(+)S KS cells have an increased expression of KSHV onco-
genes (KSHV in vivo lytic switch), paralleling our previous findings in the mouse KS-like
mECK36 model [26], and also displayed PDGFRA signaling activation that co-distributed
with KSHV LANA, thus supporting the described link between KSHV and PDGFRA activa-
tion in the tumors [14]. The pattern of KSHV expression in K-Pα(+)S KS cells-derived tumors
show an increase in lytic transcripts in vivo [26]. The importance of the “in vivo” microenvi-
ronment on affecting the KSHV expression profile was previously reported in PEL and KS [24,
75]. Although it is assumed that most spindle cells in KS lesions are latently infected [76],
KSHV lytic gene expression was also reported for a portion of KS lesions [43, 77, 78]. The
RNA-sequencing analysis for KSHV gene expression of recently reported samples [43] shown
in Fig 2B, indicates that some human KS biopsies also express lytic transcripts as found in our
mouse KSHV model, further supporting the relevance of KSHV in vivo lytic gene expression
observed in MSCs tumors (the in vivo lytic switch) to actual cases of human AIDS-KS. We pro-
pose that the fact that tumorigenic K-Pα(+)S KS cells showed enhanced expression of KSHV
lytic genes while they are able to growth in vivo, together with the results showing proliferation
of productively KSHV-infected human MSC cultures of Fig 7, provides a powerful model for
the initial steps of KSHV oncogenesis showing a definitive oncogenic role of KSHV lytic gene
expression in KS pathogenesis.
The bioinformatics-based analysis using RNA sequencing of the mouse KS-like K-Pα(+)S
tumors revealed glycolysis, NOTCH signaling and TGFB signaling among the most upregu-
lated pathways during the KSHV in vivo lytic switch, pointing, therefore, to these pathways as
important drivers of KSHV tumorigenesis in vivo. Indeed, many of these host signaling cas-
cades that are co-opted by KSHV, including PI3K/AKT/mTOR, NFkB and Notch, are critical
for cell-specific mechanisms of transformation [1, 3, 79, 80]. Importantly, recent RNA
sequencing data of KS transcriptomes compared to KS lesions show KSHV-mediated global
transcriptional reprogramming that, similarly to our MSC tumors, included upregulation of
the transforming growth factor-beta 1 (TGFB1) signaling pathway and glucose metabolism
disorders [43].
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The different KSHV transcriptional programs shown by K-Pα(+)S cells were determined
by the culture conditions where the infected cells were grown, either those for MSC pluripo-
tent growth or pro-angiogenic KS-like media. A similar pattern of differences in the KSHV
transcriptional program was shown for KSHV-infected lymphatic endothelial cells (LECs)
compared to KSHV-infected blood endothelial cells (BECs) [63]. Moreover, we showed that
multiple biological processes were enriched among the differential expressed host genes
(DEGs) between K-Pα(+)S MSC and K-Pα(+)S KS cells, indicating that KS-like culture condi-
tions which favored the transcription of KSHV lytic genes correlated with the expression of
oncogenic host-gene networks. Patterns of KSHV and host gene expression in K-Pα(+)S MSC
versus K-Pα(+)S KS cells could be explained by differences in the epigenetic regulation deter-
mined by the different culture conditions. Here, we confirm that there were less repressive his-
tone marks and more activating histone marks (H3K27me3-H3K4me3) on different portions
of the KSHV genome in K-Pα(+)S KS than in K-Pα(+)S MSC cells, that correlated with
increase KSHV gene expression by these tumorigenic cells (Fig 8). Pathway analysis of host
genes enriched with H3K27me3 in non-tumorigenic K-Pα(+)S MSC showed that the most
repressed genes were all related to KS and KSHV oncogenic signaling, further indicating that
distinct environments where KSHV infection occurs can lead to different host epigenetic land-
scape, thus prompting oncogenesis. In the K-Pα(+)S KS cells, the most repressed pathways
were linked to innate immunity, this could favor the ability of these cells to continue growing
in the presence of increased levels of KSHV gene expression while promoting lower levels of
expression of innate immune genes upon lytic reactivation. This indicates that tumorigenic
K-Pα(+)S KS cells are more adapted to withstand oncogenic KSHV lytic gene expression pos-
sibly by upregulating oncogenic pathways, but also by repressing innate immune response
genes upon induction of the lytic replication program (Fig 8).
A possible mechanism of oncogenicity in K-Pα(+)S KS cells is that these pro-angiogenic
growth conditions promote a de-repressed KSHV epigenome, which during the in vivo KSHV
lytic switch, allow for expression of oncogenic KSHV genes leading to tumorigenesis. We
found that, as shown for other infected murine cells [81] neither viral DNA replication nor
virus production was seen after KSHV reactivation with HDACi in K-Pα(+)S MSC and K-Pα
(+)S KS cells, further indicating an abortive lytic state after reactivation characteristic of KSHV
infection of murine cells. Moreover, K-Pα(+)S MSC cells stopped proliferating after KSHV
lytic reactivation in vitro and in vivo in Matrigel-plugs. Interestingly, tumorigenic K-Pα(+)S
KS were able to continue proliferating after KSHV lytic reactivation and after KSHV in vivo
lytic switch in Matrigel-plugs, in spite of enhanced KSHV oncogene expression. Evidence has
accumulated of senescence as a contributor of tumor suppression and as a host defense mecha-
nism in limiting the effects of oncogenic viruses [56, 82]. We found increased senescence
markers (SA-β-Gal positive cells, upregulation of SASP and senescence markers, increase p21
expression and decrease Ki67 expression) in non-proliferating K-Pα(+)S MSC after KSHV
lytic reactivation, indicating that this inhibitory mechanism could explain the arrest in prolif-
eration and the lack of tumor formation of these cells. In contrast, tumorigenic K-Pα(+)S KS
cells are able to proliferate in spite of p21 upregulation and enhanced KSHV lytic gene expres-
sion (Fig 8). Early steps of KSHV tumorigenesis involve activation of the DNA damage check-
points that lead to selective pressure for mutations which abrogate checkpoints, thus providing
an advantage for cells with defective DNA damage response components to propagate [57].
Accordingly, tumorigenic K-Pα(+)S KS cells are able to proliferate in the presence of DNA
damage (ƴH2AX) after KSHV reactivation. Thus, these conditions not only conferred an epi-
genetic adaptation leading to increased KSHV gene expression but also to a mechanism, which
upon in vivo lytic switch, would allow cells to overcome KSHV-driven oncogene-induced
senescence and cell cycle arrest, prompting tumorigenesis (Fig 8).
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We sought to understand the mechanisms that, after KSHV lytic reactivation, allow K-Pα
(+)S KS cells to continue growing while induced senescence of K-Pα(+)S MSC cells. An RTK
array showed that PDGFRA was the most activated kinase in K-Pα(+)S KS comparesd to K-Pα
(+)S MSC. Furthermore, the fact that K-Pα(+)S MSC display a series of RTKs that are more
activated than K-Pα(+)S KS (ErbB2, ErbB3), further indicates the unique role of PDGFRA
activation compared to activation of other RTK cascades in promoting proliferation in the
context of KSHV lytic gene expression. We have recently shown that KSHV usurps sarcoma-
genic PDGFRA signaling to drive KS through upregulation of PDGFs ligands by KSHV lytic
genes [14]. After KSHV reactivation, only K-Pα(+)S KS cells showed PDGFRA activation that
correlated with an upregulation of PDGFA and PDGFB expression. This KSHV-induced
ligand-mediated activation of PDGFRA signaling may constitute an important mechanism
mediating the adaptation of the K-Pα(+)S KS cells to continue proliferating despite KSHV
lytic gene expression.
We found that K-Pα(+)S KS cells treated with PDGFR tyrosine kinase inhibitor lost their
ability to continue proliferating upon KSHV lytic reactivation while showing increased levels
of senescence markers. Thus, the PDGFRA signaling pathway is essential to promote KSHV-
infected cell survival and proliferation allowing KSHV tumorigenesis to progress, further vali-
dating this oncogenic pathway as a therapeutic target for early stages of KS tumorigenesis (Fig
8). One approach that has been explored for the treatment of KSHV tumorigenesis is the stim-
ulation of lytic reactivation in the presence of antiviral drugs. We have previously shown that
this was effective in blocking PEL growth in mouse xenograft models [50] by the combination
of proteasome plus HDAC inhibitors. Hereby we propose that the combination of HDAC plus
PDGFR inhibitors should also constitute a plausible therapeutic approach.
It has been reported that human MSCs supported active viral lytic replication at the acute
infection stage with low proliferation rates [35]. We observed that KSHV-infected bone mar-
row-derived human MSCs (K-hMSCs) grown in MSC media produced infectious virions, and
in accordance, stop proliferating shortly after infection. However, when maintained in KS-like
pro-angiogenic environment, these KSHV-infected hMSCs proliferated at high rates even
though they showed active viral lytic replication, which correlated with higher levels of Cyclin
D1 expression and PDGFRA activation. In addition, when K-hMSCs were grown in the pres-
ence of the PDGFR inhibitor IV to abrogate PDGFRA signaling, their proliferation was abol-
ished shortly after KSHV infection. These results illustrate that, as shown for mouse MSCs, the
outcome for KSHV infection of bone marrow-derived human MSCs is strongly determined by
the culture conditions. While MSC culture conditions favor viral production, KS-like culture
conditions are more permissive for enabling PDGFRA-mediated proliferation of productively
infected hMSC cultures.
Several prior studies have pointed to the role of Mesenchymal Stem Cells (MSCs) and Lym-
phatic Endothelial Cells (LECs) as KSHV targets and KS progenitors [13, 17, 28, 34–38]. These
studies propose that Kaposi sarcoma spindle cells can arise from either KSHV-infected MSCs
through a mesenchymal to endothelial transition (MEndT) or from KSHV-infected LECs
through an endothelial to mesenchymal transition (EndMT) [83]. We showed that after KSHV
de novo infection of MSCs and LECs, all cells were lytically infected but only MSCs growing in
KS-like environment were able to proliferate. The results of Fig 7 suggest a double role for
these cells in KSHV pathobiology: pluripotent MSCs may play a role in supporting KSHV
infection/ dissemination, while the same cells in a pro-angiogenic KS-like environment might
be key precursors in KSHV sarcomagenesis. Regarding the proposed role of LECs as KS-pro-
genitors; infected LECs have been shown to undergo EndMT when growing in “in vivo” -like
conditions such as 3D spheroids and activation of notch signaling [13]. It then becomes plausi-
ble that an infected LEC could be also a KS progenitor through a first stage involving EndMT
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to become a mesenchymal PDGFR-positive KS-precursor that may undergo sarcomagenesis
in an angiogenic KS-like environment. Our results point to PDGFRA as both the key patho-
genesis driving receptor and the defining marker of the phenotype of an uninfected circulating
KS progenitor (PDGFRA-positive bone marrow-derived MSCs), therefore intervening
through the different steps of KSHV oncogenesis. PDGFs are the most powerful MSC chemo-
attractant [84] and are expressed in KSHV-infected cells in KS lesions [14, 85, 86]. We propose
that a pro-angiogenic KS-like environment rich in secreted lytic infection-driven growth fac-
tors, like PDGF, can recruit circulating Pα(+)S-derived MSCs KS progenitors infected with
KSHV and lead to tumorigenesis driven by KSHV oncogenic gene expression.
In summary, we designed a novel model of “de novo” KSHV oncogenesis based on infec-
tion of PDGFRA-positive mesenchymal stem cell progenitors cultured in pro-angiogenic/vas-
culogenic KS-like growth conditions. This system serves as a unique and robust platform to
identify KSHV oncogenic-pathways and their relationship with cellular lineages and extracel-
lular growth environments. Additionally, it can further be exploited to genetically dissect and
elucidate viral, host-cell and environmental features of KS pathobiology.
Materials and methods
Cell culture
Mouse mesenchymal stem cells (MSCs) were harvested and characterized as described previ-
ously [39]. MSCs were grown in 20% FBS (Atlanta Biologicals), 1% (vol/vol) penicillin and
streptomycin, and αMEM (Invitrogen). MSCs were characterized by (i) adherence to plastic,
(ii) negative for hematopoietic cell surface markers CD34 and CD45 and positive for CD105,
CD90.2, CD73, and stem cell antigen SCA-1; and (iii) the ability to differentiate into adipo-
cytes or osteoblast-like cells. Human MSCs were isolated as described previously [39]. Briefly,
BM aspirates (25–50 mL) were purchased from AllCells (Emeryville, CA) under appropriate
informed consent and institutional review board approval. The experiments were performed
using MSCs at passages 8–15 for murine cells and passages 4–7 for human MSCs. Human lym-
phatic endothelial cells (LECs) were purchased from ScienceCell (catalog # 2500),used at pas-
sages 2–4, cultured in fibronectin-coated culture vessels (2μg/cm2) and grown in EGM2-MV
medium from Lonza (catalog # CC-3202). HEK AD-293 cells were cultured in DMEM with
10% FBS (Gemini Bioproducts) and 1% penicillin-streptomycin (Invitrogen).
Animal studies
All mice were housed under pathogen-free conditions. Tumor studies were done in 4- to 6-
week-old nude mice obtained from Taconic Biosciences, Inc. Tumors were generated by sub-
cutaneous injection of MSC PDGFRA+ve KSHV KS cells (2 x 105 cells) as previously described
[26]. Tumor volumes were measured using a caliper every 2 days and calculated using the fol-
lowing formula: [length (mm) × width (mm)2× 0.52] [87].
Generation and maintenance of mouse PDGFRA-positive MSCs grown in
MSC or KS-like media
The isolated mouse MSC cells were infected with rKSHV.219, MOI of 3, in the presence of
polybrene (8 μg/ml) for 1 hour. 2 days later, puromycin was added to the culture to select and
expand the infected cells. All murine cells were cultured in MEM alpha media: supplemented
with 20% heat inactivated fetal bovine serum (FBS) (MSC media); or KS-like growth medium
(KS media): DMEM supplemented with 30% FBS (Gemini Bioproducts), 0.2 mg/ml Endothe-
lial Cell Growth Factor (ECGF) (Sigma-Aldrich) or (ReliaTech), 0.2 mg/ml Endothelial Cell
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Growth Supplement (ECGS) (Sigma-Aldrich), 1.2 mg/ml heparin (Sigma-Aldrich), insulin/
transferrin/selenium (Invitrogen), 1% penicillin-streptomycin (Invitrogen), and BME vitamin
(VWR Scientific).
Virus preparation and infection
iSLK-219 cells harboring recombinant KSHV 219 from Don Ganem and Myoung [88] were
used for virus preparation. Briefly, infectious viruses of the 219 strain were induced from the
respective iSLK cells by treatment with doxycycline and sodium butyrate for 4 days. The cul-
ture supernatants were filtered through a 0.45-μm filter and centrifuged at 25,000 rpm for 2 h.
The pellet was re-suspended in phosphate-buffered saline (PBS), aliquot, and stored at −70˚C
as infectious KSHV preparations. Virus infection was performed according to the method
used in a previous study, with minor modifications. Mouse MSCs, Human MSCs and human
LECs were seeded at 6 × 104 cells per well in 6-well culture plates. After a day of culture, the
culture medium was then removed and cells were washed once with PBS. The prepared KSHV
inoculum, MOI of 3 for mouse MSCs and MOI of 8 human MSCs and LECs, and 8 μg/ml of
Polybrene were mixed and added to the cultured cells. After centrifugation at 700 × g for 60
minutes, the inoculum was removed after 3 hours and 2 ml of culture medium was added to
each well. For titration of infectious virions, HEK AD-293 cells seeded in 12 wells for 24 hours
were infected with 1 ml of supernatants. At 72 hours post-infection, the GFP-positive cells
were counted by Flow Cytometry.
Detection and quantification of virion DNA
After 96 hours, post-infection, viral loads (KSHV DNA copy numbers) were determined by
real-time quantitative PCR of cell-free supernatants (virions). Cell-free supernatants were also
collected and used for de novo infection of HEK AD-293 cells in the presence of 5 ug/ul
Polybrene.
Reagents
Antibodies: Histone H3K27Ac (cat. #4353), Histone H3 (cat. #4499), AKT, and p-AKT (cat.
#4060), Ki67 (cat. #9129) and ƴH2AX (cat. #9718) were purchased from Cell Signaling Tech-
nology (Danvers, MA); p21 (cat. #ab109199) and LANA (cat. #ab4103) from Abcam (Cam-
bridge, MA), PDGFA (cat. #sc-9974), PDGFB (cat. #sc-365805), Cyclin D1 (cat. #sc-718),
FLT4/VEGFR3 (cat. #sc321) and p53 (cat. #sc-6243) from Santa Cruz Biotechnology; Actin
(cat. #A5441) from Sigma; and p-PDGFRA (Y742) (cat. #AF2114) and total PDGFRA (cat.
#AF-307) from R&D Systems (Minneapolis, MN). Anti-CD31 (PECAM1) (cat. #550274) from
BD Biosciences. PDGFR tyrosine kinase inhibitor IV (cat. # sc-205794) was purchased from
Santa Cruz Biotechnology.
Matrigel-plug
We re-suspended 2 × 106 of K-Pα(+)S MSC or K-Pα(+)S KS cells in 500 μL phenol red-free
Matrigel (BD Bioscience, cat. # 356235). The mixture was implanted subcutaneously into the
back of 7 weeks old male NUDE mice (n = 3 in each group) following the BD Bioscience pro-
tocol. Two implants were injected per mouse. As a negative control, we injected only Matrigel
(n = 3). After 1 week, the mice were euthanized, and the Matrigel plugs were removed.
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Whole-animal fluorescent imaging
Injected mice were analyzed with IVIS spectrum whole live-animal imaging system (Perkin
Elmer Inc., Waltham, MA, USA). Mice were anesthetized with isoflurane using a vaporizer,
and a fluorescence image was obtained using GFP filter set (excitation wavelength, 488 nm;
emission wavelength, 510 nm).
Flow cytometry
For analysis of PDGFRA expression, cells were diluted in FACS buffer of PBS containing 2%
FBS and 1 mM EDTA. APC-conjugated anti-PDGFRA antibody (eBioscience, cat. # 17-1401-
81), PE-conjugated anti-Sca-1 antibody (eBioscience, cat. #12-5981-81), or the isotype control
were diluted in FACS buffer at 1:200, and added to the cells for 30 min incubation at 4C. Cells
were then washed twice in cold PBS and fixed with 4% paraformaldehyde. All flow cytometry
analysis was performed on a Becton-Dickinson LSR analyzer (BDBiosciences) and analyzed
using FlowJo (Tree Star, Inc.) software.
RNA-Sequencing analysis
RNA was isolated and purified using the RNeasy mini kit (Qiagen). RNA concentration and
integrity were measured on an Agilent 2100 Bioanalyzer (Agilent Technologies). Only RNA
samples with RNA integrity values (RIN) over 8.0 were considered for subsequent analysis.
mRNA from cell lines and tumor samples were processed for directional mRNA-seq library
construction using the Preparation Kit according to the manufacturer’s protocol. We per-
formed paired-end sequencing using an Illumina NextSeq500 platform. The short-read
sequences were mapped to the mouse reference genome (GRCm38.82) by the splice junction
aligner TopHat V2.1.0. We employed several R/Bioconductor packages to accurately calculate
the gene expression abundance at the whole-genome level using the aligned records (BAM
files) and to identify differentially expressed genes between cell lines and cell lines and tumors.
Briefly, the number of reads mapped to each gene based on the TxDb. Mmusculus gene
ensembls were counted, reported and annotated using the Rsamtools, GenomicFeatures, Gen-
omicAlignments packages. To identify differentially expressed genes between cell lines and
tumor samples, we utilized the DESeq2 test based on the normalized number of counts
mapped to each gene. Functional enrichment analyses were performed using the ClueGo
Cytoscape’s plug-in (http://www.cytoscape.org/) and the InnateDB resource (http://www.
innatedb.com/) based on the list of deregulated transcripts between K-Pα(+)S KS cells and
K-Pα(+)S MSC cells (p-value<0.01; FC>±1.5) and between K-Pα(+)S KS tumors in vivo and
K-Pα(+)S KS cells in vitro (p-value <0.001; FC>±2). Data integration and visualization of dif-
ferentially expressed transcripts were done with R/Bioconductor. KSHV transcriptome was
analyzed using previous resources and KSHV 2.0 reference genome [89], while edgeR test was
employed for differential gene expression analysis of KSHV transcripts. Kaposi’s sarcoma
KSHV RNA-seq profiles were retrieved from GEO database (GSE100684) from a previous
study [43] and integrated with mouse derived samples for further analysis.
Chromatin immunoprecipitation (ChIP)
To reduce the effect of technical variation and sample processing bias, we utilized recently
described quantitative ChIP (qCHIP) sequence technology. For normalization strategies, we
obtained Drosophila melanogaster chromatin (Spike-in Chromatin) and Drosophila-specific
histone variant, H2Av antibody (spike-in antibody) from Active Motif (cat. # 61686 and cat. #
53083). The ChIP protocol used previously was modified [48] (to perform the qChIP). In brief,
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for each ChIP, chromatin prepared from 10 million cells was mixed with 50 ng Spike-in chro-
matin. This was precleared using IgG for 2 hours before being mixed with 2 μg spike-in anti-
body and 4 μg antibody specific for the epitope of interest. The antibodies used were
H3K4me3 (Abcam, cat. #ab8580), H3K27me2/3 mAb (Active Motif, cat. # 39535), control rab-
bit IgG (Santa Cruz Biotechnology, cat. #sc-2027). The antibody-chromatin mixture was incu-
bated at 4C overnight in a cold room. Next day, 20 μl protein A/G magnetic beads (Pierce, cat.
# 88802) were washed, blocked with PBS 1% BSA, added to the chromatin-antibody complex,
and incubated at 4C for 2 hours. The supernatant was removed by placing the sample on a
magnet. The beads were washed 4X with LiCl wash buffer and 1X with TE buffer. The DNA
was eluted from the immune complex bound on beads by incubating the beads at 65C in
freshly prepared 100 μl SDS elution buffer for two hours. Another elution step was performed
by incubating the beads in 50 μl elution buffer. The two portions of eluted DNA were com-
bined (150 μl) and DNA was finally purified using NEB Monarch PCR and DNA cleanup kit
(cat. #T1030S). The DNA was finally eluted in 60 μl 0.1X TE. 1 μl of eluted DNA was utilized
for ChIP-seq library preparation.
ChIP-seq library preparation
The NEB Next Ultra II DNA Library Prep Kit for Illumina (cat. # E7645L) was used for prepar-
ing libraries with the manufacturer’s protocol and associated reagents. 50 μl eluted ChIP DNA
for each sample was mixed with 3 μl of end prep enzyme mix and 7 μl end prep reaction buffer.
The end prep was carried out by incubating the reaction for 30 min at 20C and 30 min at 65C
in a thermocycler. The above reaction was mixed with 2.5 μl of 1:25 dilution of Illumina
adapter, and ligated using 60 μl ligation master mix and ligation enhancer by incubating the
reaction at 20C for 15 min. 3 μl of USER enzyme was added to carry out the reaction at 37C
for 15 min. Libraries were purified to remove unligated adaptors using AMPure XP beads. The
PCR amplification of purified adaptor-ligated fragments was performed using Q5 DNA Mas-
ter mix supplied in the kit. In total 16 libraries were generated and were multiplexed using
NEB Multiplex Oligo sets for Illumina. The libraries were pooled in two lanes of Illumina and
were sequenced on Illumina HiSeq using 2�150 run at the University of Florida ICBR facility.
KSHV ChIP-Seq analysis
The adapter sequences were trimmed from the reads using Trimmomatic [90] and the quality
of the trimmed reads was checked with FastQC. Reads were aligned to the KSHV genome
(GenBank accession number: GQ994935.1) [91] using Bowtie2 in paired-end mode [92].
Duplicates were removed with Picard, after which peaks were called using MACS2 [93]. The
peaks were scaled with respect to KSHV episome copy number and Drosophila (fly) spike-in
reads. To do the normalization, first, the data was normalized to the number of episomes. To
obtain the scaling factor, the number of episomes in the MSC input was divided by the number
of episomes in the KS input and the MSC input. This gave the KS samples a scaling factor of
approx. 1.8 and the MSC samples a scaling factor of 1. Next, the fly scaling factor was deter-
mined. This was done with the following equation for all samples: 1/(number of fly reads/
1000000). The ratio of KSHV reads to fly reads was determined by dividing KSHV reads by fly
reads. Much like step one, the episome and fly scaling factor was determined by dividing the
MSC input KSHV/fly ratio by the KS and MSC KSHV/fly ratios. Finally, the spike in episome
count was determined by multiplying the fly scaling factor and the KSHV/fly ratio. The data
were visualized using IGV.
To generate the heat maps, promoter regions were defined as 1 kb upstream and down-
stream of the translational start sites (TSS). The TSSs were determined using ORF start
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positions and annotatePeaks.pl from Homer (v4.7), which resulted in an expression matrix.
The rows display the histone modification patterns along the −1 kb to +1 kb genomic regions
relative to the translational start site (TSS) of each viral gene, which we assigned as the gene
regulatory regions. The 1 kb regions were divided into twenty 50 bp fragments and genes were
separated into IE, E, L, and latent gene classes. The resulting matrix was log transformed and
row centered before using Pearson correlation and pairwise complete-linkage hierarchical
clustering with Cluster 3.0. Clustered matrices were then visualized using Java TreeView (ver-
sion 1.1.6r4) where rows show the log2 average peak derived from the average of the biological
replicates of the ChIP-Seq experiments. Blue and yellow colors represent the lower-than-aver-
age and higher-than-average expression, respectively.
Host gene ChIP-Seq analysis
ChIP-seq reads were analyzed following the AQUAS ChIP-seq bioinformatics pipeline using
default parameters (Kundaje lab, https://github.com/kundajelab/chipseq_pipeline). Briefly,
FASTQ reads were aligned to the mouse mm9 genome using BWA v0.7.13 and duplicate reads
were removed using Picard tools v1.126. Peaks and signal tracks were generated using
MACS2.1 and filtered for blacklist regions identified by ENCODE. Bedtools v2.26.0 intersect
was used to determine peak overlaps with RefSeq genes +2.5kb upstream of TSS regions to
identify H3K27me3 and H3K4me3 enriched genes. NGS Plot v2.61 was used to generate den-
sity plots.
Soft agar assay
Base agar was made by combining melted 1% agar with KS-like medium or MSC medium to
give a 0.5% Agar/1X KS-like or MSC medium solution. 1.5 mL was added to each well of a 6
well plate and allowed to set. Five thousand cells were plated on top of base agar in 0.7% agar/
2X KS-like or MSC medium in triplicate in 6-well plates. The cells were fed every 3 days with 1
mL of Ks-like or MSC medium. Colonies were photographed at 4 weeks. Only colonies larger
than the mean size of the background colonies in the negative control wells were considered.
Real-Time Quantitative PCR (RT-qPCR)
RNA was isolated with RNeasy Plus Kit (QIAGEN, Valencia, CA) with on columns DNase
treatment. 500 ng of RNA was transcribed into cDNA using Reverse Transcription System
(Promega, Madison, WI) according to the manufacturer’s instructions. RT-qPCR was per-
formed using an ABI Prism 7000 Sequence Detection System (Applied Biosystems) with Sybr-
Green PCR Master Mix (Quanta Biosciences). In every run, melting curve analysis was
performed to verify the specificity of products as well as water and–RT controls. Data were
analyzed using the ΔΔCT method as previously described [26]. Target gene expression was
normalized to GAPDH by taking the difference between CT values for target genes and
GAPDH (ΔCT value). These values were then calibrated to the control sample to give the
ΔΔCT value. The fold target gene expression is given by the formula: 2–ΔΔCT.
Cell proliferation assay (IncuCyte)
Cells were plated in 6-well plates at 60,000 cells/well in 3 replicates. Cells were incubated in an
Incucyte Zoom (Essen Bioscience), acquiring green and red fluorescence images at 10× every
2 hours. The Incucyte Zoom software was used to analyze and plot the results.
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Immunofluorescence staining
Immunofluorescence assay (IFA) was performed as previously described [26]. Briefly, paraf-
fin-embedded tissue sections were deparaffinized and rehydrated following antigen retrieval
treatment. Cells were fixed in 4% paraformaldehyde for 10 min and washed with PBS. Tumor
section and cells were permeabilized in 0.2% Triton-X/PBS for 20 min at 4˚C. After blocking
with 3% of BSA in PBS and 0.1% Tween 20 for 60 min, samples were incubated with Primary
antibodies overnight at 4C. After PBS washing, samples were incubated with fluorescent sec-
ondary antibodies for 1 hour (Molecular Probes), washed and mounted with ProLong Gold
antifade reagent with DAPI (Molecular Probes). Images were taken using a Zeiss ApoTome
Axiovert 200M microscope.
Western blotting
Protein concentrations in cell and tumor lysates were quantified using the DC Protein Assay
(Bio-Rad,). 20 μg of proteins were mixed with Laemmli buffer, boiled for 5 min, resolved by
SDS-PAGE and transferred to PVDF membranes (Bio-Rad Laboratories). Membranes were
blocked with 3% BSA for 1 hour and incubated with primary antibodies (4C, 16 hours). After
3 TBS/T washes, membranes were incubated with HRP-labeled secondary antibodies (Pro-
mega) for 1 hour at room temperature. Protein bands were developed using ECL Plus Detec-
tion Reagents (GE Healthcare). To analyze multiple proteins on the same membrane,
membranes were washed with Restore PLUS Western Blot Stripping Buffer (Thermo Scien-
tific) according to the manufacturer’s protocol.
Phospho-Receptor Tyrosine Kinase (RTK) array
R&D Systems’ Mouse Phospho-Receptor Tyrosine Kinase (RTK) Array Kit (Catalog #
ARY014) was used to detect levels of phosphorylation of 39 RTKs in K-Pα(+)S MSC or K-Pα
(+)S KS cells.
Statistical analysis
Statistical significance of the data was determined using two-tailed Student’s t-test and 2way
ANOVA for multiple comparisons. A p-value lower than 0.05 was considered significant. Sta-
tistical analysis was performed using GraphPad Prism 7. All values were expressed as
means ± standard deviation.
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